Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00891436 · ClinicalTrials.gov registry record · Phase 4
Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms
A Phase 4 study of Allergic Conjunctivitis to Tree Pollen or Grass Pollen, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00891436 is a Phase 4 study of Allergic Conjunctivitis to Tree Pollen or Grass Pollen that has completed, run by Rush University Medical Center. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00891436, a Phase 4 study of Allergic Conjunctivitis to Tree Pollen or Grass Pollen, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Rationale and objectives: Fluticasone furoate nasal spray (Veramyst) has been shown to improve ocular symptoms when used for the treatment of seasonal allergic rhinitis during the ragweed pollen season. Although this is the only published report of an intranasal corticosteroid shown to effectively treat ocular symptoms, the mechanism has not been delineated. Furthermore, the tears of patients with allergic conjunctivitis are known to have increased concentrations of cytokines and allergic mediators. The objective of this study is to determine if the positive effects of Veramyst nasal spray on ocular symptoms is via the inhibition of allergic mediators in the eyes. The investigators will conduct a double blind placebo controlled trial to determine if Veramyst nasal spray decreases the amount of allergic mediators in the tears of subjects randomized to Veramyst nasal spray versus placebo. The investigators will also compare the subjects' symptoms to the amount of allergic mediators detected in their tears.
Conditions Studied
Interventions
- DRUG Placebo nasal spray
- DRUG Fluticasone furoate nasal spray
Study Locations (1)
Illinois
- Rush University Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00891436
The ClinicalTrials.gov registry entry for NCT00891436 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis to Tree Pollen or Grass Pollen appearing as the primary indexed condition, and to 2 interventions - of which Placebo nasal spray is the first listed.
NCT00891436 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00891436 about?
NCT00891436 is a clinical study titled "Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms". Rationale and objectives: Fluticasone furoate nasal spray (Veramyst) has been shown to improve ocular symptoms when used for the treatment of seasonal allergic rhinitis during the ragweed pollen season. Although this is the only published report of an intranasal corticosteroid shown to effectively ...
What is the current status of trial NCT00891436?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2009-04. Estimated completion is 2009-08.
What conditions does trial NCT00891436 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis to Tree Pollen or Grass Pollen.
What interventions are being tested in trial NCT00891436?
The interventions under investigation include: Placebo nasal spray (DRUG), Fluticasone furoate nasal spray (DRUG).
Who is sponsoring clinical trial NCT00891436?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00891436 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.